CLAIMS

1. Use of ~~C~~cystamine or cysteamine, or a salt thereof, for ~~use in~~ the manufacture of a medicament for treating a ~~MECP2-associated disorder~~ neurodevelopmental and/or neurological disorder that is caused by MeCP2 expression defects in a patient.

2. ~~Cystamine or cysteamine for~~ The use ~~in treating a MECP2-associated disorder~~ according to claim 1, wherein the ~~MECP2-associated~~ disorder is selected from the group consisting of Rett syndrome, autism, Pervasive development disorder, non-syndromic mental retardation, idiopathic neonatal encephalopathy and idiopathic cerebral palsy.

3. ~~Cystamine or cysteamine for~~ The use ~~in treating a MECP2-associated disorder~~ according to claim 2, wherein the ~~MECP2-associated~~ disorder is Rett syndrome.

4. ~~Cystamine or cysteamine for~~ The use ~~in treating a MECP2-associated disorder~~ according to any of claims 1 to 3, for use in combination with another pharmaceutically active compound.

5. The use according to any of claims 1 to 4, wherein cystamine or cysteamine is to be administered orally.

~~5. A calcineurin inhibitor for use in treating a MECP2-associated disorder in a human patient.~~

~~6. The calcineurin inhibitor for use in treating a MECP2-associated disorder according to claim 5, which is a macrolide.~~

~~7. The calcineurin inhibitor for use in treating a MECP2-associated disorder according to claim 5 or 6, which is selected from the group consisting of calcipressins, tacrolimus and tacrolimus analogs, cyclosporine A and cyclosporine A analogs, LxPV proteins, 2,6-diaryl-substitued pyrimidine derivatives and FK506-binding proteins~~

8. The calcineurin inhibitor for use in treating a MECP2-associated disorder according to claim 7, which is selected from the group consisting of calcipressin 1, calcipressin 2, calcipressin 3, tacrolimus, ascomycin, sirolimus, pimecrolimus, cyclosporine A, voclosporine, LxPVc1, LxPVc2, LxPVc3, 6-(3,4-dichloro-phenyl)-4-(*N*,*N*-dimethylaminoethylthio)-2-phenyl-pyrimidine and FK506-binding protein 8.

9. The calcineurin inhibitor for use in treating a MECP2-associated disorder according to claim 8, which is tacrolimus.

10. The calcineurin inhibitor for use in treating a MECP2-associated disorder according to claim 8, which is yclosporine A.

11. The calcineurin inhibitor for use in treating a MECP2-associated disorder according to any of claims 5 to 9, wherein the MECP2-associated disorder is selected from the group consisting of Rett syndrome, autism, Pervasive development disorder, non-syndromic mental retardation, idiopathic neonatal encephalopathy and idiopathic cerebral palsy.

12. The calcineurin inhibitor for use in treating a MECP2-associated disorder according to claim 11, wherein the MECP2-associated disorder is Rett syndrome.

13. The calcineurin inhibitor for use in treating a MECP2-associated disorder according to any of claims 5 to 12, for use in combination with another pharmaceutically active compound.

14. Use of cystamine or cysteamine, or a salt thereof for the manufacture of a medicament for treating a MECP2-associated disorder in a patient.

15. Use according to claim 14, wherein the MECP2-associated disorder is selected from the group consisting of Rett syndrome, autism, Pervasive development disorder, non-syndromic mental retardation, idiopathic neonatal encephalopathy and idiopathic cerebral palsy.

16. Use according to claim 15, wherein the MECP2-associated disorder according to claim 2, wherein the MECP2-associated disorder is Rett syndrome.

17. Use according to any of claims 14 to 16, in combination with another pharmaceutically active compound.

18. Use of a calcineurin inhibitor for the manufacture of a medicament for treating a MECP2-associated disorder in a human patient.

19. Use according to claim 18, wherein the calcineurin inhibitor is a macrolide.

20. Use according to claim 18 or 19, wherein the calcineurin inhibitor is selected from the group consisting of calcipressins, tacrolimus and tacrolimus analogs, cyclosporine A and cyclosporine A analogs, LxPV proteins, 2,6-diaryl-substitued pyrimidine derivatives and FK506-binding proteins.

21. Use according to claim 20, wherein the calcineurin inhibitor is selected from the group consisting of calcipressin 1, calcipressin 2, calcipressin 3, tacrolimus, ascomycin, sirolimus, pimecrolimus, cyclosporine A, voclosporine, LxPVc1, LxPVc2, LxPVc3, 6-(3,4-dichloro-phenyl)-4-(*N*,*N*-dimethylaminoethylthio)-2-phenyl-pyrimidine and FK506-binding protein 8.

22. Use according to claim 21, wherein the calcineurin inhibitor is tacrolimus.

23. Use according to claim 21, wherein the calcineurin inhibitor is yclosporine A.

24. Use according to any of claims 18 to 23, wherein the MECP2-associated disorder is selected from the group consisting of Rett syndrome, autism, Pervasive development disorder, non-syndromic mental retardation, idiopathic neonatal encephalopathy and idiopathic cerebral palsy.

25. Use according to claim 24, wherein the MECP2-associated disorder is Rett syndrome.

26. Use according to any of claims 18 to 24, in combination with another pharmaceutically active compound.